Digestive Disease Interventions 2020; 04(04): 365-368
DOI: 10.1055/s-0040-1718903
Review Article

Immunoembolization of Liver Metastases from Uveal Melanoma

David J. Eschelman
1   Division of Interventional Radiology, Department of Radiology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania
,
Marlana M. Orloff
2   Division of Solid Tumor, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
› Author Affiliations

Abstract

The authors review the use of immunoembolization as a liver-directed treatment for uveal melanoma metastatic to the liver.



Publication History

Received: 21 July 2020

Accepted: 19 August 2020

Article published online:
16 November 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Aronow ME, Topham AK, Singh AD. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973–2013). Ocul Oncol Pathol 2018; 4 (03) 145-151
  • 2 Eschelman DJ, Gonsalves CF, Sato T. Transhepatic therapies for metastatic uveal melanoma. Semin Intervent Radiol 2013; 30 (01) 39-48
  • 3 Grisanti S, Tura A. Uveal melanoma. In: Scott JF, Gerstenblith MR. eds. Noncutaneous Melanoma. Brisbane, Australia: Codon Publications; 2018: 1-18
  • 4 Seedor RS, Eschelman DJ, Gonsalves CF. et al. An outcome assessment of a single institution's longitudinal experience with uveal melanoma patients with liver metastasis. Cancers (Basel) 2020; 12 (01) 117
  • 5 Sato T, Nathan PD, Hernandez-Aya L. et al. Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: overall survival findings. J Clin Oncol 2018; 36: 9521
  • 6 Helgadottir H, Höiom V. The genetics of uveal melanoma: current insights. Appl Clin Genet 2016; 9: 147-155
  • 7 Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now?. Ther Adv Med Oncol 2018; 10: 1758834018757175
  • 8 Heppt MV, Amaral T, Kähler KC. et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J Immunother Cancer 2019; 7 (01) 299
  • 9 Kanai T, Monden M, Sakon M. et al. New development of transarterial immunoembolization (TIE) for therapy of hepatocellular carcinoma with intrahepatic metastases. Cancer Chemother Pharmacol 1994; 33 (Suppl): S48-S54
  • 10 Yoshida T, Sakon M, Umeshita K. et al. Appraisal of transarterial immunoembolization for hepatocellular carcinoma: a clinicopathologic study. J Clin Gastroenterol 2001; 32 (01) 59-65
  • 11 Saito T, Tsuchiya T, Sato Y. et al. Effect of transarterial immunoembolization as preoperative treatment for hepatocellular carcinoma. Ann Cancer Res Therap 2011; 19: 26-33
  • 12 Nakamoto Y, Mizukoshi E, Kitahara M. et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Clin Exp Immunol 2011; 163 (02) 165-177
  • 13 Patel K, Sullivan K, Berd D. et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 2005; 15 (04) 297-304
  • 14 Sato T, Eschelman DJ, Gonsalves CF. et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2008; 26 (33) 5436-5442
  • 15 Dranoff G, Jaffee E, Lazenby A. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90 (08) 3539-3543
  • 16 Sullivan KL. Immunoembolization for melanoma. In: Geschwind JFH, Soulen MC. eds. Interventional Oncology: Principles and Practice. New York: Cambridge University Press; 2008: 311-315
  • 17 Sullivan KL, Aoyama T, Sato T, McCue P. Safety of immunoembolization of normal swine liver with human GM-CSF (granulocyte macrophage colony stimulating factor) and ethiodol. J Vasc Interv Radiol 2001; 12: S132-S133
  • 18 Yamamoto A, Chervoneva I, Sullivan KL. et al. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology 2009; 252 (01) 290-298
  • 19 Valsecchi ME, Terai M, Eschelman DJ. et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J Vasc Interv Radiol 2015; 26 (04) 523-32.e2
  • 20 Gutjahr CJ, Gonsalves CF, Eschelman DJ, Frangos A, Meshekow JS, Sato T. Immunoembolization (IE) using 1500 mcg of granulocyte macrophage-colony stimulating factor (GM-CSF) and 2 million IU of interleukin-2 (IL-2) for the treatment of uveal melanoma (UM) hepatic metastases. J Vasc Interv Radiol 2014; 25: S26
  • 21 Guez D, Eschelman D, Pan K. et al. Ipilimumab combined with immunoembolization for treatment of uveal melanoma metastatic to the liver. J Vasc Interv Radiol 2019; 30: S141
  • 22 Ford R, Gonsalves C, Adamo R. et al. Prolonged survival after treatment of hepatic uveal melanoma metastases using immunoembolization. J Vasc Interv Radiol 2019; 30: S140